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Abstract
Background: Coronary Heart Disease (CHD) remains a major cause of mortality in the United Kingdom. Yet predictions of
future CHD mortality are potentially problematic due to population ageing and increase in obesity and diabetes. Here we
explore future projections of CHD mortality in England & Wales under two contrasting future trend assumptions.
Methods: In scenario A, we used the conventional counterfactual scenario that the last-observed CHD mortality rates from
2011 would persist unchanged to 2030. The future number of deaths was calculated by applying those rates to the 2012–
2030 population estimates. In scenario B, we assumed that the recent falling trend in CHD mortality rates would continue.
Using Lee-Carter and Bayesian Age Period Cohort (BAPC) models, we projected the linear trends up to 2030. We validate our
methods using past data to predict mortality from 2002–2011. Then, we computed the error between observed and
projected values.
Results: In scenario A, assuming that 2011 mortality rates stayed constant by 2030, the number of CHD deaths would
increase 62% or approximately 39,600 additional deaths. In scenario B, assuming recent declines continued, the BAPC model
(the model with lowest error) suggests the number of deaths will decrease by 56%, representing approximately 36,200
fewer deaths by 2030.
Conclusions: The decline in CHD mortality has been reasonably continuous since 1979, and there is little reason to believe it
will soon halt. The commonly used assumption that mortality will remain constant from 2011 therefore appears slightly
dubious. By contrast, using the BAPC model and assuming continuing mortality falls offers a more plausible prediction of
future trends. Thus, despite population ageing, the number of CHD deaths might halve again between 2011 and 2030. This
has implications for how the potential benefits of future cardiovascular strategies might best be calculated and presented.
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Introduction
The halving of UK Coronary Heart Disease (CHD) death rates
(mortality) since the 1970s represents a major public health
achievement. However, CHD still remains the leading cause of
premature death (before 75 years) and years of life lost (YLLs) in
the UK [1]. Strategies to maximise the prevention of CHD and
cardiovascular disease (CVD) therefore remain a top policy
priority. The English government recently suggested that the
NHS Health Checks programme might prevent or postpone
approximately 650 cardiovascular deaths per annum [2].
From the late 1980s, scientists started to recognise early signs of
a deceleration in previous CHD mortality declines. In the United
States, the annual rate of decline for men aged 35 to 54 fell from
6.2% per annum in the 1980s to 0.5% in the 2000s [3]. Similar
warning trends were discovered in other countries: England and
Wales [4], Scotland [5], the Netherlands [6] and Australia [7]. In
England and Wales, CHD mortality declines were not just slowing
[4] but in 2002 for the first time in over two decades, CHD
mortality increased among men aged 35–44 years.
CHD mortality rises approximately exponentially with age.
Thus the population ageing now occurring in most industrialised
countries could drive a higher CHD burden in future years. This
shift in population density to older ages has been driven by
continued reductions in mortality, and the influx of birth cohorts
from the first and second baby boom generations, who are now
approaching retirement age [8]. It is therefore not surprising that
by 2030, the largest predicted shifts in age distribution are
anticipated in the older groups aged 65 and beyond: 35% among
those 65–74 years old, 50% among those aged 75–84, and 89% in
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those aged 85 and beyond. This is truly a dramatic shift in
population density to older ages.
The result will be a rapid and sustained rise in numbers of UK
patients requiring care for both morbid and fatal CHD events. In
the US, Heidenreich et al. [9] predicted that around 40.5% of the
population will have some form of CVD by 2030. In England and
Wales, the only certainty is that the increasing burden of CHD will
place a huge strain on the National Health Service and on
informal carers [10].
Forecasting mortality (all-cause and disease-specific) is the art
and science of demographers, actuaries, epidemiologists and policy
makers. The range of methods includes parameterisation models
(i.e. mortality laws), the widely applied Lee-Carter method, age
period cohort models, statistical models for mortality and
morbidity and dynamic multi-state models (see Booth and Tickle
[11] and Tabeau et al. [12] for a review of methods).
There have been several forecasts of the potential future of
CVD burden: Heidenreich et al. [9], Huovinen et al. [13], Odden
et al. [14], Huffman et al. [15], Heidenreich et al. [16] and
Ovbiagele et al. [17]. However, these forecasts have used the
assumption that any current decline in CVD morbidity and
mortality will cease at the beginning of the forecast period. In
other words, the prevalence and mortality rates are held constant
when projecting numbers of cases and deaths into the future. The
International Diabetes Federation also assumes constant rates to
predict future global burden of the disease [18].
Perhaps of more concern is the evidence that policy makers use
similar approaches. For example, the English NHS Health Checks
programme is based on the assumption that the risk of dying from
CVD will persist unchanged in the future [19]. This sudden
cessation of mortality decline would represent a catastrophic (and
hopefully unlikely) deterioration of UK public health.
Therefore the aim of this paper was to contrast the predictions
made under the assumption of a sudden cessation of mortality
decline in England and Wales with predictions made under the
assumption of continuation of recent declines.
Methods
We obtained data on the number of CHD deaths from 1979–
2011, stratified by gender and 10-year age groups (35 to older than
85 years) in England and Wales, from the Office of National
Statistics (ONS). CHD is defined as codes 410–414 and I20–I25 in
the 9th and 10th versions respectively, of the International
Classification of Diseases. Mid-year population estimates were
obtained from the same source along with 2010-based population
projections for the period 2012–2030. From these data, we
computed mortality as the central deaths rate from CHD.
Scenarios
In scenario A we assumed a conventional counterfactual, that
the last-observed levels of CHD mortality (in 2011) would persist
unchanged. To obtain indirect standardised estimates of the future
number of CHD deaths, we multiplied this CHD mortality by the
forecast population numbers.
In scenario B we assumed that the recent trends in CHD
mortality rates might continue. We evaluated two conventional
models to forecast CHD mortality rates from 1979 to 2011: the
Lee-Carter model [20] and the hierarchical Bayesian Age Period
Cohort (BAPC) model [21]. To assess the prediction performance
of both models, we used data from 1979 to 2001 to predict
mortality rates from 2002 to 2011. Then, we computed the mean
absolute percent error (MAPE, see Text S2 in Appendix S1)
between those projections and the observed rates from the same
period of time. The model with the lowest MAPE was used to
forecast the number of CHD deaths (using the population
projections until 2030).
We then investigate the difference between the forecasts from
scenario A and the best model from scenario B. We show this in
terms of forecast CHD mortality rates and number of CHD
deaths.
Finally, we assessed the prediction performance of scenario A
and scenario B using MAPE, in the same manner as when
comparing the Lee-Carter and BAPC models.
Lee-Carter and BAPC models. Lee and Carter [20]
developed a method to forecast mortality that combines a
demographic model with time-series methods of forecasting. The
basic idea behind the model is that a single parameter (mortality
index) governs the dynamics of a mortality trend. It is the most
widely-used method for forecasting future mortality and numerous
extensions have been developed in the last decades.
Let mx,t be the central mortality rate for age x in year t t, the
model states
ln mx,tð Þ~axzbxktz"x,t
Where kt is the mortality index at time t, ax is the average pattern
of mortality by age, bxis the relative change with respect to the
mortality index at age x and Ex,t is the residual at age x and year t.
We fitted the basic Lee-Carter model to our data using the R
package demography [22]. Because we have data available only in
10-year age-groups, prior to fitting the model, we used monotonic
regression splines for smoothing [23].
Because of it is nature, Lee-Carter models are more suitable for
forecasting mortality trends characterised by a strong period
component effect, such as infectious respiratory diseases [24].
Period effects might capture temporal change in factors associated
with medical and broader societal development. However, we
expect that (albeit potentially small) cohort effects are also
important to the aetiology of CHD. Cohort effects capture
generational differences temporal change in life-course factors by
year of birth. The BAPC model allows investigating the additional
cohort effects in mortality along with age and period effects.
The BAPC model assumes the logit of the mortality probability
from CHD in age group i in period j is a linear combination of an
intercept m, age effects hi i~1, . . . Ið Þ, period effects Qj j~1, . . . Jð Þ






I is the total number of age groups and J the total number of
periods. Cohorts are defined by k~C I{ið Þzj and the total
number of cohorts is K~C I{1ð ÞzJ, where C is the width of the
age bands. In our data, I = 6, C = 10 and J = 33, hence there are
K = 83 cohort parameters.
We estimated the age, period and cohort effects between 1979
and 2011 and then let each of these components continue along
their last observed linear trends. Then we extrapolated the
resulting trajectory to 2030. We also re-estimated the model by
adding a parameter that estimates unobserved heterogeneity in the
input data not explained by age, period and cohort effects.
The models were implemented in the Bayesian Age-Period-
Cohort Modeling and Prediction software (BAMP) [25] which uses
Markov Chain Monte Carlo (MCMC) for the model estimation.
We evaluated the goodness of fit of the models with and without
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the heterogeneity parameter using the Deviation Information
Criterion (DIC) [26] which also penalises for model complexity.
Finally, to assess the importance of the cohort (along with age
and period) effects for CHD mortality, we re-estimated the model
by relaxing some assumptions imposed to the parameters (see Text
S1C in Appendix S1). For more details about the BAPC
methodology, please see Text S1 in Appendix S1. For more
details about the software, please see Schmid and Held [25].
Results
Lee-Carter vs BAPC Model
According to the DIC values (Table 1), the best fitting BAPC
model was the model with the heterogeneity parameter. Smaller
DICs indicate a better supported, more parsimonious model. The
strong support for a heterogeneity parameter indicates that there
was still substantial unexplained variation around our main model
fit.
Figures 1 and 2 show the CHD mortality rates estimated by the
Lee-Carter and BAPC models. Both models suggest mortality
rates, for each gender and at all ages, will follow a continuing but
decelerating trajectory of decline to 2030. In particular, for the
middle age groups (45–54, 55–64 and 65–74) both models predict
a substantial slowing of the decline. Additionally, the Lee-Carter
differs from the BAPC model in predicting a slower decline at the
eldest ages.
We initially validated each model by projecting mortality from
2002–2012 based on data from 1979–2001, and subsequently
compared our projections with the observed data. Figures 3 and 4
show the projected and observed values. The BAPC model
provides a very good fit, although for age groups 65–74 and 75–84
in men and women, it predicted slower declines than observed.
The Lee-Carter model highly overestimated those above 55 years
of age. In terms of MAPE (see Figure 5), The BAPC model had a
lower percentage error than the Lee-Carter model. Thus, although
both models agreed mortality will continue to decline, we choose
the BAPC model to continue our analysis as it had better
predictive performance.
Interpretation of the age, period and cohort effects. To
estimate the age, period and cohort effects from the BAPC model,
we need to relax the restrictions imposed to the model (see Text
S1C in Appendix S1). The results suggest that the age effect
explained most variation; followed by the period effect, and then
the cohort effect.
Constant Future Mortality Versus Continuing Declines
Mortality rates. Figures 6 and 7 show the projected CHD
mortality rates under scenario A (constant 2011 levels of CHD
mortality) and scenario B (the BAPC model). In scenario B,
mortality rates for each gender and at all ages follow a continuing
but decelerating, trajectory of decline to 2030. The expected rate
of future decline is notably faster at ages 75–84 and older,
especially in males: over age 85, future CHD mortality could fall
by a difference of 1,270 deaths per 100,000 individuals [95%
credible interval (95% CrI) 1,065–1,386] in females, and by 1,770
deaths per 100,000 individuals (95% CrI 1,470–2,000) in males.
However, for the middle age groups (45–54, 55–64 and 65–74) the
BAPC model in scenario B predicts a clear slowing of mortality
decline.
Number of deaths. If CHD mortality remains at its 2011
level (scenario A), by 2030 we can expect that the total number of
CHD deaths will increase substantially by 67% [95% confidence
interval (95% CI) 65%–68%] for men and 54% (52%–55%) for
women; with an overall increase of 62% (61%–63%) or 39,600
deaths. This is due to population ageing, which increases the
number of people present at older ages, thus generating more
CHD deaths. However, if recent declines in CHD mortality
continue (scenario B), the BAPC model suggested that absolute
number of deaths would decrease by 49% (95% CrI 24%–68%)
for men and by 66% (43%–81%) for women, yielding a total
decrease of 56% (29%–74%) or 36,200 deaths. Figure 8 shows the
total observed numbers of CHD deaths and projections under
both scenarios. We can observe that the number of deaths has
fallen rapidly since the 1980s. If CHD mortality is assumed to stay
constant at 2011 levels then the past trend reverses abruptly, to a
rapid increase in CHD deaths. In stark contrast, the BAPC
projects a continuing decline, albeit at a decelerating rate.
These results are consistent with the projections stratified by age
group and gender (Figures 9 and 10). In scenario B, we no longer
see pronounced decline in deaths among men and women as
evident as in the mortality rates, due to the future influx of people
into the oldest age classes (.75 years) which slows the decline in
number of deaths. Similarly, we observe a clear slowing in the
decline of absolute numbers of deaths for middle groups 45–54,
55–64 and 65–74.
It is striking how opposite the trends with scenario A are to the
natural trend observed in the last 30 years. The BAPC model
projections continue the past trends and lead to a powerful
conclusion: The projected CHD mortality declines are more than
adequate to counteract the wave of additional CHD deaths that
would be generated by population ageing.
Finally to assess the prediction performance of both scenarios,
we estimated the number of deaths from 2002–2012 and
compared these with the actual observed values. For scenario A,
we projected mortality rates at 2001. For scenario B, we used data
from 1979–2001 to re-estimate the model. Figures 11 and 12 show
the predictions and observed values. Scenario A highly overesti-
mated the number of deaths, whereas scenario B provides a
reasonable fit. In terms of MAPE (see Figure 13), scenario A had a
consistently higher percentage error than scenario B.
Discussion
Main Findings
We evaluated two scenarios in relation to future estimates of
CHD deaths. In scenario A, we assumed that the mortality rates in
2011 would persist and remain unchanged until 2030. Under this
Table 1. DIC values for BAPC models with and without heterogeinity parameter.
Model Men Women
BAPC 1122 1438
BAPC + heterogeneity 381 349
Smaller DICs indicate a better supported more parsimonious model. See Text S1B in Appendix S1 for details of the model fits.
doi:10.1371/journal.pone.0099482.t001
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very conservative assumption, we estimated that the total numbers
of CHD deaths would increase substantially by 67% for men and
by 54% for women. These predicted rises reflect the demographic
changes that England and Wales will experience in the next
decades, notably population ageing. However, in scenario B by
simply assuming that the recent declines in CHD mortality might
Figure 1. CHD mortality rates for men: Observed rates, Lee-Carter and BAPC projections.
doi:10.1371/journal.pone.0099482.g001
Figure 2. CHD mortality rates for women: Observed rates, Lee-Carter and BAPC projections.
doi:10.1371/journal.pone.0099482.g002
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continue, our estimates of the future burden of CHD mortality are
substantially lower (249% for men and 266% for women).
Lee-Carter vs BAPC
We compared two commonly used methods to forecast
mortality: The Lee-Carter model and the Bayesian estimation of
an APC model. Because we found a very small cohort effect in the
CHD mortality trends, it was expected that both models would
Figure 3. Validation of mortality rates for men 2002–2011: Observed rates, Lee-Carter and BAPC projections.
doi:10.1371/journal.pone.0099482.g003
Figure 4. Validation of mortality rates for men 2002–2011: Observed rates, Lee-Carter and BAPC projections.
doi:10.1371/journal.pone.0099482.g004
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Figure 5. Mean absolute percent error between predicted (Lee-Carter and BAPC) and observed rates by age group and gender.
doi:10.1371/journal.pone.0099482.g005
Figure 6. CHD mortality rates for men: Scenario A and Scenario B.
doi:10.1371/journal.pone.0099482.g006
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Figure 7. CHD mortality rates for women: Scenario A and Scenario B.
doi:10.1371/journal.pone.0099482.g007
Figure 8. Total number of CHD deaths 1979–2030.
doi:10.1371/journal.pone.0099482.g008
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give similar results. Indeed both models projected declines in
mortality up to 2030.
However, when their prediction performance was evaluated,
Lee-Carter seemed to perform poorly for the eldest groups. Why
Lee-Carter tends to underestimate mortality decline in the eldest
Figure 9. CHD deaths for men: Scenario A and Scenario B.
doi:10.1371/journal.pone.0099482.g009
Figure 10. CHD deaths for women: Scenario A and Scenario B.
doi:10.1371/journal.pone.0099482.g010
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groups may be because the ratio of rates of proportional mortality
change (i.e. the change in log mortality) at different ages is
assumed to remain constant over time [11]. Therefore Lee-Carter
is relatively insensitive to trends in the age-pattern of mortality
change. Indeed, as Darkiewicz and Hoedemakers [27] shown for
all-cause mortality data for England and Wales, it is not unusual
Figure 11. Validation of mortality rates for men 2002–2011: Observed rates, Scenario A and Scenario B.
doi:10.1371/journal.pone.0099482.g011
Figure 12. Validation of mortality rates for women 2002–2011: Observed rates, Scenario A and Scenario B.
doi:10.1371/journal.pone.0099482.g012
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for the age-pattern of mortality change to vary over time. These
authors also fitted a Lee-Carter model and found that the model
seriously under-estimated mortality decline for elderly men and
women. This issue with Lee-Carter has been thoroughly discussed
and methods to deal with it has been suggested by Booth et al. [28]
and Carter and Prskawetz [29] among others. Thus, our use of the
BAPC model also seems advantageous on statistical grounds.
Comparison with other Studies
Many of the previous studies assuming constant mortality rates
(scenario A) also reported projected estimates of the number of
future CHD deaths. For example, the Coronary Heart Disease
Policy Model is a complex Markov model that simulates the future
incidence, prevalence and mortality from CVD in the U.S [14].
Their results suggested that if no significant changes in risk factors
or treatment occur in the future, the annual number of CHD
deaths will increase by 56% over the next 30 years. Similarly,
Huovinen et al. [13] predicted an increase in deaths among
Finnish men and women aged 60 and older, including an alarming
202% increase in deaths among men aged 80 and older. Also,
Huffman et al. [15] reported that if risk factor trends and mortality
rates in the U.S. population remain constant (at the 2006 level),
there could be an increase of 12% in absolute numbers of deaths
by 2020.
However, as we have demonstrated, the assumption of mortality
remaining constant appears neither realistic nor valid. The
consequent predictive error can be vast, for example, an early
version of the Coronary Heart Disease Policy Model (1987)
predicted that by 2010 the total number of CHD deaths in the US
would be around 630,000 [30]. However, the observed value
(380,000 deaths, [31]) in 2010 was substantially lower, barely half
their prediction.
In contrast, our scenario B assumes (not unreasonably) that
recent mortality trends may continue for some time into the future.
Under this more plausible scenario, we suggest that the total
number of deaths in England and Wales in 2030 could decrease
substantially by 47% in men and by 66% in women.
Huovinen et al. [13] used a similar BAPC analysis to predict
CHD mortality in Finland. Their results are very similar to ours,
except for the oldest group: They predicted that the number of
deaths among men aged 80 and older would increase more than
four-fold between 2002 and 2030, and almost three-fold among
women. Although this could reflect population differences between
the UK and Finland, it might also reflect differences in the model
assumptions: Huovinen held the APC components constant over
the forecast period whereas we allowed their trends to continue
(see Text S1A in Appendix S1). In addition, the CrIs for the oldest
group are particularly wide, highlighting the difficulty of reliable
predictions for the elderly. For example, for men 80 and older,
Huovinen’s 95% CrIs range between 474 and 2,620 deaths.
Cohort Effects
Another interesting result from our scenario B (BAPC model) is
that the most important factor for CHD mortality in both sexes is
age, followed by period and cohort effects. Cohort has a very small
effect. There is contradictory evidence regarding whether there
are detectable cohort effects on CHD mortality. APC models built
for Australia [32] and New Zealand [33], and other descriptive
Figure 13. Mean absolute percent error between predicted (Scenario A and B) and observed rates by age group and gender.
doi:10.1371/journal.pone.0099482.g013
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analyses carried out for Poland and Hungary [34], suggested the
absence of any cohort effect. In contrast, modest cohort effects in
CHD mortality were reported in Singapore [35] and Norway [36],
and a descriptive study in Hong Kong [37] found cohort effects for
women but not for men. Such conflicting evidence may be
partially attributable to the fact that most of the studies claim
cohort effects are caused by events that operate during the
perinatal period [38]. On the other hand, the major changes in
cardiovascular risk factors have been period-based changes to
lifestyle and treatments [32]. Cohort effects can also be a
consequence of influences later in life. For example, social
attitudes regarding lifestyle could be the result of new cohorts
with different risk behaviours replacing older cohorts [39].
Strengths and Weaknesses
The BAPC model offers some further important advantages: the
classical APC model allows mortality to be described as trends
over age at death, year of death and birth cohort, and to model
extra heterogeneity if it is needed. Likewise, the Bayesian setting
exhibits some interesting features that increase the reliability and
interpretability of our predictions: Prior information (e.g. results of
a previous model or expert opinion) can be used to guide the
inference made from the current data. The Bayesian approach
estimates the probability distribution of the parameters, given the
data. This yields a full probability model that, unlike frequentist
methods, can be used to generate a probability distribution of
possible futures. This probabilistic distribution of futures can be
summarised by 95% credible intervals, which are probabilistic
regions around the estimates and differs from frequentist
confidence intervals by allowing direct comparison among the
probabilities of possible futures.
In addition, Bayesian models are unbiased with respect to the
sample size; therefore, the model works well with smaller numbers
of cases [40], which is useful when modelling women and younger
groups.
However, our projections also have limitations that should be
acknowledged. First, the projections are calculated using future
estimates of population (produced by the ONS). These population
projections are based on a number of assumptions regarding
future levels of fertility, migration and mortality. All can present
difficult tasks for demographers and statisticians [41] and the
estimates produced may be biased. However, one possible solution
would be to fit BAPC models separately for different levels of
migration.
Second, our projections assume that effects of the age, period
and cohort components will remain unchanged into the future.
However, CHD mortality can sometimes change dramatically
over a short period of time. These ‘‘black swan’’ events are
undirected and retrospectively unpredictable [42]. For example,
following the break-up of the Soviet Union in 1989, profound
changes in diet in Poland and neighbouring countries were
associated with sudden large decreases in CVD deaths commenc-
ing in 1990 [43,44]. Equally rapid CVD mortality falls were
observed in Cuba after a sharp and substantial reduction in calorie
intake during their so called ‘‘special period’’ of the early 1990’s.
The lag times observed were consistently less than five years
[45,46]. Even more rapid rises and falls in CVD mortality have
recently been observed in Russia, partly reflecting the dramatic
fluctuations in consumption of alcohol [47,48]. Similarly, rapid
decreases in mortality have been seen after smoke-free legislation
in Scotland and in other populations [49].
In contrast, CHD rates can demonstrate a lag time of one or
two decades following increases in obesity or diabetes [50]. The
continuing dramatic rises in obesity and diabetes prevalence in the
UK, coupled with recent flattening in blood pressure and
cholesterol trends in the last decade, make predictions about the
future evolution of the CHD epidemic extremely uncertain [51–
54]. Even assuming constant mortality rates (our scenario A),
Huffman et al. demonstrated that, simply by considering plausible
changes in the risk factors trends, their results varied by 27% from
their baseline (no-changes) scenario [15].
Conclusions and Policy Implications
The global public health community is increasingly focussing on
strategies to control non-communicable diseases [55]. Thus, past
and current trends in risk factors and mortality might give health
service planners useful insights on the evolution of the CHD
epidemic. However, we will need disease burden forecast
methodologies which exploit the increasingly detailed causal
knowledge of CVD. Department of Health modelling has
suggested that the English NHS Health Checks programme might
prevent or postpone approximately 650 cardiovascular deaths per
annum. However, that figure might represent a serious over-
estimate, because it assumes that the risk of dying from CVD will
persist unchanged in the future [19]. If so, this makes the estimated
annual cost of NHS Health Checks of approximately £300 million
look even more substantial.
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38. Baker D, Illsley R, Vågerö D (1993) Today or in the past? The origins of
ischaemic heart disease. Journal of Public Health 15: 243–248.
39. Bell A, Jones K (2013) The impossibility of separating age, period and cohort
effects. Social science & medicine.
40. (C-Projections) CPN (2010) Long-Term Projection Methods: Comparison of
Age-Period-Cohort Model-Based Approaches. Alberta Health Services: 2010–
2012.
41. Wood J, Horsfield G, Vickers L (1999) The new subnational population
projections model: methodology and projection scenarios. Population Trends
98: 21–28.
42. Taleb NN (2007) The Black Swan: the impact of the highly improbable.
London: Penguin.
43. Zatonski WA, Willett W (2005) Changes in dietary fat and declining coronary
heart disease in Poland: population based study. BMJ 331: 187–188.
44. Zatonski W, Campos H, Willett W (2008) Rapid declines in coronary heart
disease mortality in Eastern Europe are associated with increased consumption
of oils rich in alpha-linolenic acid. European journal of epidemiology 23: 3–10.
45. Franco M, Ordunez P, Caballero B, Granados JAT, Lazo M, et al. (2007)
Impact of energy intake, physical activity, and population-wide weight loss on
cardiovascular disease and diabetes mortality in Cuba, 1980–2005. American
Journal of Epidemiology 166: 1374–1380.
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